Canton Strategic Holdings, Inc.
CNTN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CNTN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNTN
Canton Strategic Holdings, Inc. (CNTN) is a biopharmaceutical company developing a pipeline of product candidates including TH104 (a transmucosal buccal film for opioid prophylaxis and pruritus), HS3215 (a HER2/HER3 bispecific antibody), and HS1940, with a focus on advancing clinical trials and securing regulatory approvals.
Key risk: Clinical trial uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$176.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Canton Strategic Holdings, Inc. (CNTN) is a biopharmaceutical company developing a pipeline of product candidates including TH104 (a transmucosal buccal film for opioid prophylaxis and pruritus), HS3215 (a HER2/HER3 bispecific antibody), and HS1940, with a focus on advancing clinical trials and securing regulatory approvals.
- Cash and equivalents of $37.2M as of 2026-06-30 [sec].
- Total revenue of $1.5M and net loss of -$19.3M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $397.9M as of 2026-06-30 [sec].
- Pipeline includes TH104 (buccal film for opioid prophylaxis and pruritus), HS3215 (HER2/HER3 bispecific antibody), and HS1940 [sec_mda · as of 2025-08-14].
- Research and development expenses decreased by 52% to $3.1M for the year ended December 31, 2025, from $6.4M in 2024 [sec_mda · as of 2026-03-31].
What works
- Diversified pipeline targeting multiple indications (opioid prophylaxis, pruritus, oncology) with distinct mechanisms (buccal film, bispecific antibody) [sec_mda · as of 2025-08-14].
- Licensed INT-023/TH023, an oral anti-TNF-α monoclonal antibody (infliximab), expanding into inflammatory disease space [sec_mda · as of 2025-11-12].
- Cash position of $37.2M as of 2026-06-30 provides near-term operational runway [sec].
What to weigh
- Net loss of -$19.3M for the six months ended 2026-06-30 indicates ongoing cash burn [sec].
- Research and development expenses decreased significantly, which may reflect deprioritization of earlier candidates (e.g., HSB-1216) [sec_mda · as of 2026-03-31].
- Uncertainty in clinical trial duration, costs, and regulatory approval for all product candidates [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
Pipeline includes TH104, HS3215, and HS1940
“Develop TH104 as a transmucosal buccal film product for temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with high-potency opioids;”
SEC MD&A · August 14, 2025
Research and development expenses decreased by 52% in 2025
“Research and development expenses decreased by $3.3 million, or 52%, to $3.1 million for the year ended December 31, 2025 fro”
SEC MD&A · March 31, 2026
Risks & what to watch (3)›
Key risks
- Clinical trial uncertainty — Duration, costs, and timing of clinical trials for HS3215 and HS1940 are uncertain [sec_mda · as of 2026-05-13].
- Regulatory approval risk — May never succeed in obtaining marketing approval for any product candidate [sec_mda · as of 2026-05-13].
- Cash burn and net losses — Net loss of -$19.3M for six months ended 2026-06-30, with no guarantee of future revenue [sec].
What to watch
- Initiation and progress of clinical trials for HS3215 and HS1940 [sec_mda · as of 2026-03-31].
- Regulatory developments for TH104, including NDA filing requirements [sec_mda · as of 2025-11-12].
- Cash runway and potential need for additional financing given net losses [sec].
Sources: SEC MD&A · Generated August 15, 2026 · How we verify sources →
Run Canton Strategic Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Canton Strategic Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.24 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
0 buys · 8 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
37
Total value held
$30.6M
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 3,695,084 | $12.1M |
| vanguard capital management llc | 905,360 | $3.0M |
| blackrock, inc. | 765,829 | $2.5M |
| amova asset management americas, inc. | 728,167 | $2.4M |
| renaissance technologies llc | 562,000 | $1.8M |
| geode capital management, llc | 440,112 | $1.4M |
| millennium management llc | 359,183 | $1.2M |
| feynman point asset management llc | 350,568 | $1.1M |
| bienville capital management, llc | 216,802 | $709K |
| vanguard fiduciary trust co | 211,445 | $691K |
Showing top 10 of 37 institutional holders of Canton Strategic Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.1%
- Days to cover
- 5.3
- Shares short
- 3,327,475
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNTN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Canton Strategic Holdings, Inc.?
Canton Strategic Holdings, Inc. (CNTN) is a biopharmaceutical company developing a pipeline of product candidates including TH104 (a transmucosal buccal film for opioid prophylaxis and pruritus), HS3215 (a HER2/HER3 bispecific antibody), and HS1940, with a focus on advancing clinical trials and securing regulatory approvals.
Who is the CEO of Canton Strategic Holdings, Inc.?
Mr. Mark Wendland is the chief executive officer of Canton Strategic Holdings, Inc. (CNTN).
Where is Canton Strategic Holdings, Inc. headquartered?
Canton Strategic Holdings, Inc. (CNTN) is headquartered in Red Bank, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.